PedAM
Pediatric Disease Annotations & Medicines
| Disease | liver disease |
| Phenotype | C0011860|type 2 diabetes mellitus |
| Sentences | 21 |
| PubMedID- 26573192 | [body mass index is a risk factor for new-onset non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus]. |
| PubMedID- 20353583 | This study aimed to examine the importance of serum endotoxin and inflammatory markers in non-alcoholic fatty liver disease (nafld) patients, with and without type 2 diabetes mellitus (t2dm), and to explore the effect of treatment with a lipase inhibitor, orlistat, on their inflammatory status. |
| PubMedID- 26573193 | Objective: to explore the relationship between socioeconomic status (ses) and non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 24071688 | Objective: to observe the effect of metformin on the expression of sirt1 and ucp2 in rat liver of type 2 diabetes mellitus (t2dm) with nonalcoholic fatty liver disease (nafld), and discuss the pathogenesis of t2dm with nafld, and the treatment with and possible mechanism of metformin. |
| PubMedID- 23113121 | Nafld is a common liver disease strongly associated with obesity, type 2 diabetes mellitus and hyperlipidemia (2). |
| PubMedID- 25966055 | Role of apn and tnf-alpha in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease. |
| PubMedID- 24667697 | The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. |
| PubMedID- 23954219 | Objective: to investigate the relationship between the resistin intronic +299g/a polymorphism and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 25885947 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 26381272 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. |
| PubMedID- 20625647 | Objective: to evaluate the frequency of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (dm2) and to describe its risk factors. |
| PubMedID- 25303488 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 26198953 | Objective: to investigate the association of serum pigment epithelium-derived factor (pedf) level and polymorphisms in pedf gene promoter region -358g-->a with non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm) of han nationality in fujian province. |
| PubMedID- 23489256 | Aim: the aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld). |
| PubMedID- 24919218 | [advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus]. |
| PubMedID- 26147768 | Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. |
| PubMedID- 26011302 | Background: nonalcoholic fatty liver disease (nafld) is associated with obesity, type 2 diabetes mellitus, and dyslipidemia. |
| PubMedID- 22024083 | Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. |
| PubMedID- 22927782 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. |
| PubMedID- 25877002 | The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus. |
| PubMedID- 25739820 | We identified and summarized longitudinal studies that, supporting the association of nonalcoholic fatty liver disease with either type 2 diabetes mellitus or metabolic syndrome, suggest that nonalcoholic fatty liver disease precedes the development of both conditions. |
Page: 1